Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + Anlotinib + Chemotherapy as Neoadjuvant Therapy in Early-stage TNBC
NCT04877821Phase 2Completed
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Sep 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, anlotinib in triple-negative breast cancer (TNBC), sponsored by Guangdong Provincial People's Hospital. Started Sep 2021; status: completed.
02
Drugs
sintilimabanlotinib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04877821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04877821.